Recommendations on how to find out what patients PREFER

On 28 April 2022 the PREFER project launched recommendations on why, when and how to assess and use patient preferences in medical product decision-making. During the launch, we presented take-home messages from the PREFER Recommendations. Missed the event? Don’t worry! A recording is now available!

In the presentation, we explain when and why structured input from patient preference studies can support decision making. We also describe the PREFER framework for how to do a preference study, how to identify and involve key stakeholders, how to pick the right method for your research questions, explore the impact of psychological constructs on preference heterogeneity, and how different approaches and educational materials can support patients' understanding, giving you more reliable results.


Want to know more? Watch the recorded presentation. You are welcome to download slides from this presentation, or read the PREFER Recommendations in full. For those who want a shorter read, we have also published a brief summary of the recommendations.

By Josepine Fernow





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).